Zobrazeno 61 - 70
of 240
pro vyhledávání: '"Ana Barac"'
Autor:
Riccardo Asteggiano, Bonnie Ky, Alain Cohen-Solal, Dan Lenihan, Carlo G. Tocchetti, Markus S. Anker, Stephan von Haehling, Hadi Skouri, Javid Moslehi, Frank Ruschitzka, Peter A. Henriksen, Thomas M. Suter, Jean-Sébastien Hulot, Susan Dent, Teresa López Fernández, Jereon Bax, Mitja Lainscak, Alexander R. Lyon, Eva Simona Hägler-Laube, Radek Pudil, Fortunato Ciardiello, Daniela Cardinale, Dimitrios Farmakis, Ana Barac, Zaza Iakobishvili, Martin Štěrba, Susanna Stanway, Andrew J.S. Coats, Rudolf A. de Boer, Christian Mueller, Petar M. Seferovic, Ovidiu Chioncel, Christoph Maack, Massimo F Piepoli, Jutta Bergler-Klein, Y N Belenkov, Jelena Čelutkienė
Publikováno v:
European Journal of Heart Failure. 22:1966-1983
Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases in cardiac biomarkers including cardiac troponin and natriuretic pept
Autor:
Irma Zhang, Ana Barac
Publikováno v:
Current oncology reportsPapers of particular interest, published recently, have been highlighted as: • Of importance. 24(8)
This review summarizes current HER2-targeted therapies and clinical studies that have investigated primary and secondary prevention of cardiac dysfunction for HER2 + breast cancer patients undergoing targeted therapy.Primary and secondary prevention
Autor:
Johann Bauersachs, Petar M. Seferovic, Teresa López-Fernández, Ovidiu Chioncel, Ronald M. Witteles, Michael G. Fradley, Bonnie Ky, Daniel J. Lenihan, Thomas Thum, Dragana Milojkovic, Paaladinesh Thavendiranathan, Javid Moslehi, Michael J. Mauro, Frank Ruschitzka, Thomas M. Suter, John D. Groarke, Jutta Bergler-Klein, Charlotte Manisty, Li Ling Tan, Vincent Khoo, Ariane Vieira Scarlatelli Macedo, Radek Pudil, Ashutosh Wechelaker, Dimitrios Farmakis, Y N Belenkov, Susan Dent, Hugues de Lavallade, Chris Plummer, Susannah Stanway, Alain Cohen-Solal, Tomas G. Neilan, Alexander R. Lyon, Fortunato Ciardiello, Andrew J.S. Coats, M. Sol Andres, Daniela Cardinale, Hadi Skouri, David Wright, Ana Barac, Christoph Maack, Stuart D. Rosen, Christine Brezden-Masley, Zaza Iakobishvili, Robert F. Cornell, Markus S. Anker, Aaron L. Sverdlov, Helena M. Earl, Carlo G. Tocchetti, Ludhmila Abrahão Hajjar, Stephan von Haehling, Joerg Herrmann, Rudolf A. de Boer
Publikováno v:
European Journal of Heart Failure. 22:1945-1960
This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk strat
Autor:
Bonnie Ky, Paaladinesh Thavendiranathan, Amitoj Singh, Vigyan Bang, David M. Venesy, Michael G. Fradley, Aarti Asnani, Ana Barac, Simarjeet Brar, Rohan Parikh, Katherine Shreyder, Sarju Ganatra, Joerg Herrmann, Sachin P. Shah, Tomas G. Neilan, Salim S. Hayek, Sourbha S. Dani, Paolo Mascari, Richard D. Patten, Frederic S. Resnic, Rushin Patel, Dipti Gupta, Daniel J. Lenihan, Avirup Guha, Monika Leja, Anju Nohria
Publikováno v:
Trends in Cardiovascular Medicine
Patients with pre-existing cardiovascular disease and risk factors are more likely to experience adverse outcomes associated with the novel coronavirus disease-2019 (COVID-19). Additionally, consistent reports of cardiac injury and de novo cardiac co
Autor:
Raja Zaghlol, Daniel Addison, Ana Barac, Abhishek Deshmukh, P. Elliott Miller, Rebecca R. Carter, Nihar R. Desai, Grant McKinley, Avirup Guha, Amit K. Dey
Publikováno v:
Journal of Cardiac Surgery. 35:2275-2278
BACKGROUND Inferior vena cava filter (IVCF) use is common after a venous thromboembolic event (VTE). Cancer is associated with higher rates of VTEs and is also seen in a significant proportion of patients requiring IVCF. As hospital readmissions rema
Autor:
Sylvia Wassertheil-Smoller, Theodore M. Brasky, Mara Z. Vitolins, W. Gregory Hundley, Wendy E. Barrington, April Morgenroth, Eric J. Chow, Jessica Chubak, Marian C. Limacher, Ana Barac, Matthew Barnhart, Richard Cheng, Laurel A. Habel, Matthew P. Banegas, Rebecca D. Jackson, Aaron K. Aragaki, Kerryn W. Reding, Ralph B. D'Agostino, Rowan T. Chlebowski, Chu Chen
Publikováno v:
Oncologist
Background Recent clinical trials have evaluated angiotensin-converting enzyme (ACE) inhibitors (ACEis), angiotensin receptor blockers (ARBs), and beta blockers (BBs) in relation to cardiotoxicity in patients with cancer, typically defined by ejectio
Publikováno v:
ESC Heart Failure
ESC Heart Failure, Vol 7, Iss 3, Pp 1056-1063 (2020)
ESC Heart Failure, Vol 7, Iss 3, Pp 1056-1063 (2020)
Aims Takotsubo cardiomyopathy (TC) is characterized by transient ventricular impairment, often preceded by emotional or physical stress. Racial differences affect the outcomes of several cardiovascular conditions; however, the effect of race on TC re
Autor:
Giorgio Minotti, Adam Torbicki, Bijoy K. Khandheria, Daniela Cardinale, Ana Barac, Daniel J. Lenihan
Publikováno v:
Seminars in Oncology. 46:408-413
Session III of the Second International Colloquium on Cardio-Oncology focused on the diagnosis, management, and prevention of cardiovascular toxicity of cancer drugs. With a large menu of biomarkers and imaging modalities available to the cardio onco
Autor:
Miguel-Angel Perales, Joseph R. Carver, Daniel J. Lenihan, Sarju Ganatra, Thomas J. Ryan, Monika Leja, Negaresh Mousavi, Bonnie Ky, Vlad G. Zaha, Richard M. Steingart, Eric H. Yang, Jae H. Park, Jennifer E. Liu, Ana Barac, Salim S. Hayek, Marielle Scherrer-Crosbie, Carrie Lenneman
Publikováno v:
Journal of the American College of Cardiology. 74:3153-3163
Chimeric antigen receptor (CAR) T-cell therapy has significantly advanced the treatment of patients with relapsed and refractory hematologic malignancies and is increasingly investigated as a therapeutic option of other malignancies. The main adverse
Publikováno v:
Cardiology Clinics. 37:407-418
Trastuzumab targets the human epidermal growth factor receptor 2 (HER2). Its overexpression occurs in 25% of breast cancers and is associated with aggressive tumor characteristics and poor prognosis in absence of targeted therapy. Trastuzumab dramati